High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma
| Autor: | Ryuji Ohashi, Toshiyuki Takeshita, Zenya Naito, Kousuke Ishino, Yuki Minagawa, Mitsuhiro Kudo, Ryuichi Wada |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Cyclin-Dependent Kinase Inhibitor p21 Cancer Research Programmed cell death Apoptosis Western blot Cell Line Tumor Carcinoma medicine Humans Aged Cell Proliferation Ovarian Neoplasms Cisplatin medicine.diagnostic_test business.industry General Medicine Middle Aged medicine.disease Gene Expression Regulation Neoplastic Checkpoint Kinase 2 Oncology Cell culture Checkpoint Kinase 1 Clear cell carcinoma Cancer research Female Tumor Suppressor Protein p53 business Immunostaining DNA Damage medicine.drug |
| Zdroj: | Anticancer Research. 40:5631-5639 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.14576 |
| Popis: | Background/aim DNA damage response (DDR), wherein p21 is a cell fate determinant, is a potential cancer therapeutic target. Molecular expression during DDR was explored in ovarian clear-cell carcinoma (CCC). Materials and methods CHK1, CHK2, TP53 and p21 expression in DDR was examined using immunostaining in surgical sections of CCC (n=22). Molecular alterations in two types of CCC cell lines, JHOC-5 and JHOC-9, were investigated using western blot analysis. Results Expression of DDR-associated molecules was noted in most patients. While high p21 expression was found in half of the patients, the remaining patients exhibited low p21 expression. Treatment with UC2288, a p21 inhibitor, attenuated proliferation of both cell lines, more prominently in JHOC-9, resulting in reduced viability and subsequent apoptosis. Conclusion p21 Inhibitor induced cell death in cells with high p21 expression, suggesting that p21 suppression can be a therapeutic strategy to treat patients with CCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|